

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 180.00120101	Serial No.: 10/591,199
	Applicant(s): Zhao Yi Wang	Confirmation No.: 4302
	Application Filing Date: June 13, 2007	Group: 1647
	Information Disclosure Statement filed: January <u>18</u> , 2010	

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		5,312,752	05/17/94	Wotiz et al.			

U.S. PATENT APPLICATIONS BY SERIAL NUMBER

Examiner Initial	Copy Enclosed	Document Number	Filing Date	Name	Class	Subclass
		<i>None</i>				

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		<i>None</i>						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Acs et al., "Immunohistochemical Expression of Erythropoietin and Erythropoietin Receptor in Breast Carcinoma," <i>Cancer</i> , 2002 September 1; 95(5):969-981.
	X	Fukazawa et al., "Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated Extracellular-regulated Kinase (ERK) Pathway," <i>Molecular Cancer Therapeutics</i> , 2002 March; 1:303-309.
	X	Renzi, et al., "Erythropoietin down regulates SHP1 and induces a sustained activation of ERK1/ERK2 in primary cortical neurons," <i>Blood</i> , 2001 November 16; 98; 1 page - abstract only.

EXAMINER	Date Considered
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	